Jasmina Koeva-Balabanova
Research Subjects
Jasmina Koeva-Balabanova has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Beata Jagielska
Maria Skłodowska-Curie National Research Institute of Oncology, 00-001 Warszawa, Poland
1 shared publication - Birute Tumiene
Vilnius University Hospital Santariskiu Klinikos, 08661 Vilnius, Lithuania
1 shared publication - Denis Horgan
European Alliance for Personalised Medicine, Brussels, Belgium
1 shared publication - Dipak Kalra
Department of Public Health and Primary Care, Unit of Medical Informatics and Statistics, Ghent University, Ghent, Belgium
1 shared publication - Ettore Capoluongo
Department of Clinical Pathology, San Giovanni Addolorata Hospital, Rome, Italy
1 shared publication - Ivana Cattaneo
Novartis Farma SpA, 21042 Origgio, Italy
1 shared publication
Latest Publications
- Open Access
- 23 August 2022
- Published by MDPI AG in Healthcare
- Vol. 10 (9) , 1600
Making Sure That Orphan Incentives Tip the Right Way in Europe
The delicate balance of funding research and development of treatments for rare disease is only imperfectly achieved in Europe, and even the current provisional equilibrium is under a new threat from well-intentioned policy changes now in prospect that could—in addition to the intrinsic complexities of research—reduce the incentives on which commercial activity in this area is dependent. The European Union review of its pharmaceutical legislation, for which proposals are scheduled to appear before the end of 2022, envisages adjusting the decade-old incentives to meet objectives that are more precisely targeted. However, researchers, physicians, patients and industry have expressed concerns that ill-considered modifications could have unintended consequences in disrupting the current balance and could reduce rather than increase the flow of innovative treatments for rare diseases.
- 23 August 2022
- Published by MDPI AG in Healthcare
- Vol. 10 (9) , 1600
Open AccessMaking Sure That Orphan Incentives Tip the Right Way in Europe
The delicate balance of funding research and development of treatments for rare disease is only imperfectly achieved in Europe, and even the current provisional equilibrium is under a new threat from well-intentioned policy changes now in prospect that could—in addition to the intrinsic complexities of research—reduce the incentives on which commercial activity in this area is dependent. The European Union review of its pharmaceutical legislation, for which proposals are scheduled to appear before the end of 2022, envisages adjusting the decade-old incentives to meet objectives that are more precisely targeted. However, researchers, physicians, patients and industry have expressed concerns that ill-considered modifications could have unintended consequences in disrupting the current balance and could reduce rather than increase the flow of innovative treatments for rare diseases.